Jyong Biotech (MENS) Total Non-Current Liabilities (2024 - 2025)
Jyong Biotech's (MENS) quarterly Total Non-Current Liabilities came in at $10.9 million in Q4 2025, down 64.65% year-on-year from $30.8 million in Q4 2024, and down 66.63% quarter-over-quarter from $32.6 million in Q2 2025.
Jyong Biotech (MENS) Total Non-Current Liabilities (2024 - 2025) Analysis & Trends
Jyong Biotech's Total Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $10.9 million for Q4 2025.
- On a quarterly basis, Total Non-Current Liabilities fell 64.65% year-over-year to $10.9 million in Q4 2025; TTM through Dec 2025 was $10.9 million, a 64.65% decrease from a year earlier, with the FY2025 full-year figure at $10.9 million, down 64.65% from the prior year.
- Total Non-Current Liabilities declined to $10.9 million in Q4 2025 per MENS's latest filing, from $32.6 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $32.6 million in Q2 2025 and bottomed at $10.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Jyong Biotech | 197.86 Mn | 197.86 Mn | - | 10.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 10.87 Mn |
| Jun 30, 2025 | 32.59 Mn |
| Dec 31, 2024 | 30.76 Mn |